Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 8, 2025

Study Completion Date

December 8, 2025

Conditions
Lung Cancer Stage III
Interventions
DRUG

Almonertinib

Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.

All Listed Sponsors
lead

Laibin People's Hospital

OTHER

NCT05994339 - Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer | Biotech Hunter | Biotech Hunter